Richter receives positive feedback for new contraceptive
Hungarian pharmaceutical company Gedeon Richter and Belgian peer Mithra Pharmaceuticals have said the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion for a new combined oral contraceptive containing 15 mg estetrol (E4) and 3mg drospirenone (DRSP), according to an announcement on the website of the Budapest Stock Exchange.
Subject to approval by the European Commission, the marketing authorization valid for the European Union is expected to be granted by the end of Q2 2021, the companies said.
Richter will market the product in Europe under the brand name Drovelis. The company announced a partnership with Mithra in September 2018 to sell the oral contraceptive in Europe, Russia and other CIS countries under a different brand name. Mithra sells the contraceptive under the Estelle brand.
Oral contraceptives are Richter's top-selling products.
SUPPORT THE BUDAPEST BUSINESS JOURNAL
Newspaper organizations across the globe have struggled to find a business model that allows them to continue to excel, without compromising their ability to perform. Most recently, some have experimented with the idea of involving their most important stakeholders, their readers.
We would like to offer that same opportunity to our readers. We would like to invite you to help us deliver the quality business journalism you require. Hit our Support the BBJ button and you can choose the how much and how often you send us your contributions.